

Thomas von Koch proposed as new Chairman of the Board

The Nomination Committee of Bactiguard Holding AB (publ) has today held a meeting and decided to propose Thomas von Koch as new Chairman of the Board at the Annual General Meeting on April 28, 2021. The current Chairman of the Board, Christian Kinch, is proposed by the Nomination Committee as new Deputy Chairman of the Board. Cecilia Edström has announced that she is available for re-election and is proposed by the Nomination Committee to be re-elected as a board member.

Furthermore, the Nomination Committee proposes the following:

- That remuneration to (non-employed) board members elected by the Annual General Meeting shall be paid as follows: SEK 750,000 each to the Chairman of the Board and the Deputy Chairman of the Board, and SEK 200,000 each to Cecilia Edström and Jan Ståhlberg. A remuneration of SEK 400,000 is proposed to the board member, Anna Martling. The higher compensation is justified by the value that Anna Martling's medical expertise has for Bactiguard's future development.
- For work as Chairman of the Audit Committee, it is proposed that SEK 100,000 is paid. No special remuneration is proposed to the Chairman of the Remuneration Committee and other committee members.
- The Nomination Committee's proposal means that the total board compensation will be reduced by SEK 100,000 compared to what was decided at the 2020 Annual General Meeting.

The nomination committee's full proposal will be presented in the notice to the Annual General Meeting, which will be held on April 28.

The Nomination Committee of Bactiguard consists of Helena Borglund, appointed by KK Invest AB and Chairman of the Nomination Committee, Thomas von Koch, appointed by Bactiguard B.V., Mats J Andersson, appointed by Nordea Fonder, Jan Ståhlberg, and Per Colleen, appointed by the Fourth AP Fund.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2021-02-03, at 22:15.



For further information, please contact:

Gabriella Caracciolo, CFO and deputy CEO, mobile +46 72 141 62 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes Hydrocyn® aqua, a non-alcoholic product line for wound care and disinfection. Hydrocyn effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.

Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com